Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer

Durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment then alone as adjuvant treatment after radical cystectomy is indicated for 'the treatment of adults with resectable muscle-invasive bladder cancer'.

The dosage schedule is available in the summary of product characteristics for durvalumab.

The list price of durvalumab is £592.00 per 2.4‑ml vial and £2,466.00 per 10‑ml vial. The list price of cisplatin is £5.36 per 10‑ml vial. The list price of gemcitabine varies by pack size and dose.

The company has a commercial arrangement. This makes durvalumab available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, the Carbon Reduction Plan for UK carbon emissions is published on AstraZeneca's webpage on sustainability.